Materials for the Administration of Human Genetic Resources
Release Date:
2023-03-30 16:57
I. Approval for the Collection of Human Genetic Resources in China
Application Form Template Download:
https://fuwu.most.gov.cn/r/cms/zwpt/web/assets/pdf/Collection_of_Audits.zip
II. Approval for the Preservation of China’s Human Genetic Resources
Application Form Template Download: https://fuwu.most.gov.cn/r/cms/zwpt/web/assets/pdf/Quality Assurance Template.doc
III. Approval for International Collaborative Scientific Research Involving China’s Human Genetic Resources
Application Form Template Download: https://fuwu.most.gov.cn/r/cms/zwpt/web/assets/pdf/National_Collaborative_Science_and_Technology_Research_Accreditation.zip
IV. Approval for the Export of China’s Human Genetic Resources
Application Form Template Download:
https://fuwu.most.gov.cn/r/cms/zwpt/web/assets/pdf/Materials_Review.zip
V. Filing of International Collaborative Clinical Trials Involving China’s Human Genetic Resources
Application Form Template Download: https://fuwu.most.gov.cn/r/cms/zwpt/web/assets/pdf/National Joint Testing Project Template.doc
VI. Filing for the External Provision or Open Access to Information on China’s Human Genetic Resources
Application Form Template Download: https://fuwu.most.gov.cn/r/cms/zwpt/web/assets/pdf/Information_Sheets_and_Folders.zip
VII. List of Materials to Be Submitted via the Online Filing System
1 Application Form (Attachment)
2. The business license or organizational code certificate, and the legal person certificate of this entity
3. Supporting documentation specifying the Chinese-side and foreign-side institutions
Application Form Template Download:
https://fuwu.most.gov.cn/r/cms/zwpt/web/assets/pdf/ktwssbxttjclqd.docx
Related News
818 Breakthrough Technology | Integrated Culture Protocol for γδ T Cells
The implementation of the “818 Regulations” marks the official entry of China’s cell therapy industry into a new phase of standardized development, one that prioritizes clinical efficacy as the benchmark for value, upholds rigorous compliance across the entire value chain as an inviolable baseline, and harnesses differentiated technological innovation as the core driver of progress. The Regulations explicitly restrict low-level duplication and homogeneous competition, while giving priority to the translation of technology pathways that demonstrate clear clinical value and outstanding scientific innovation, thereby establishing clear compliance boundaries and a well-defined innovation orientation for the industry’s future development.
Conference Announcement | Hycells cordially invites you to join the 3rd Boao Lecity Stem Cell Summit
From March 20 to 22, 2026, the Third Boao Lecity Stem Cell Conference, co-hosted by the China Anti-Aging Promotion Association and Hainan University, will be held in Boao Lecity, Hainan. With the theme “Cell Therapy Pioneering the Third Medical Revolution,” the conference will also make a major announcement of the latest batch of cell therapy procedures that are now permitted to be billed, thereby establishing an international high-end platform that brings together cutting-edge ideas, translates research into clinical practice, fosters industry collaboration, and jointly develops policies and standards.
A Tribute to the Woman Who Provides “Cell-Level” Protection in the Field of Life Sciences
In the world of biopharmaceuticals, cells are the fundamental units of life; at Hycells Biotechnology, women are the driving force behind global progress. From relentless pursuit in the laboratory to compassionate care on the clinical front lines, women’s sensitivity, resilience, and wisdom—like the “primary cell” technology we have meticulously cultivated—harness the most primal and essential power to propel innovation and shape the future of our field.
Hycells Biotechnology is a biotechnology innovation company specializing in research on primary immune cells and hepatocytes. We are committed to providing customers with comprehensive, one-stop solutions for immune cells and stem cells, leveraging scientific innovation to drive industry development and delivering expert services to empower clinical research.
3.0 High-Efficiency NK Serum-Free Culture Kit | Chapter 1: Cord Blood–Derived CBNK
Hycells Biotechnology’s newly launched 3.0 High-Efficiency Serum-Free NK Cell Culture Kit (Catalog No.: NK888-2L), in collaboration with the CBMC Seed Bank, provides a comprehensive, integrated cell culture solution: from thawing and recovering CBMC seed stocks or directly and efficiently expanding fresh CBMCs, to ultimately obtaining NK cells with high purity and high viability. This integrated culture system supports flexible expansion based on cell status, with a scalable culture volume of up to 10 liters, delivering outstanding culture performance and exceptional cost-effectiveness, and earning widespread trust and recognition from customers.
New Product | Hycells Announces the Launch of High-Viability Primary Hepatocyte Cells!
Within 4 hours after recovery, its cytochrome P450 enzyme activity is most similar to that in vivo, making it suitable for short-term metabolic studies.